NCT04155801View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of Salix Probiotic Blend in Participants With Functional Gastrointestinal Disturbances

NACompletedINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

October 11, 2019

Primary Completion Date

February 14, 2020

Study Completion Date

February 14, 2020

Conditions
Functional Gastrointestinal Disorders
Interventions
DIETARY_SUPPLEMENT

Salix Probiotic Blend

Oral capsule. The probiotic strains comprise the Salix Probiotic Blend include 3 strains of Bifidobacterium lactis (Bl-04®, Bi-07®, HN019) and 2 strains of lactobacillus (Lactobacillus acidophilus \[NCFM\]® and Lactobacillus paracasei \[Lpc-37\]®).

Trial Locations (1)

78209

Bausch Site 001, San Antonio

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT04155801 - A Study to Assess the Efficacy and Safety of Salix Probiotic Blend in Participants With Functional Gastrointestinal Disturbances | Biotech Hunter | Biotech Hunter